Hepatic arterial chemotherapy in metastatic colorectal patients.

Abstract:

:Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug was given as an hepatic arterial infusion (HAI) versus systemic administration. However, the studies did not accurately define survival for the following reasons: (1) some allowed a crossover; (2) some were too small; and (3) some used inadequate systemic chemotherapy. Patients who have failed to respond to previous systemic chemotherapy have an approximately 50% response rate with HAI treatment. Hepatic toxicity, especially biliary sclerosis, is the dose-limiting toxicity, occurring in 6% to 25% of patients. Adding dexamethasone to HAI fluoropyrimidine decreases the hepatobiliary toxicity. The therapeutic benefit of HAI in one study was also demonstrated by an increased time with normal quality of life. To truly define the role of regional therapy in patients with CRC confined to the liver, the current Cancer and Leukemia Group B (CALGB) study is randomizing patients to HAI versus systemic therapy without a crossover to demonstrate if HAI improves survival and/or quality of life in addition to response rates.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Kemeny NE,Ron IG

subject

Has Abstract

pub_date

1999-10-01 00:00:00

pages

524-35

issue

5

eissn

0093-7754

issn

1532-8708

journal_volume

26

pub_type

杂志文章,评审
  • Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.

    abstract::It has been a challenge to find effective chemotherapeutic treatments for malignant mesothelioma. Over the last several decades numerous single-drug and combination regimens have been examined, but no standard treatment with chemotherapy alone has emerged. Possible explanations for this lack of success are the heterog...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.30231

    authors: Baas P

    更新日期:2002-02-01 00:00:00

  • Radiation therapy in pregnancy: risk calculation and risk minimization.

    abstract::The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Greskovich JF Jr,Macklis RM

    更新日期:2000-12-01 00:00:00

  • Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane used in routine clinical practice, has aroused considerable interest for its high single-agent activity against breast cancer and for its novel mechanism of action. Epirubicin, the 4' epimer of doxorubicin, is another agent with a high a...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lück HJ,Thomssen C,du Bois A,Untch M,Lisboa B,Köhler G,Diergarten K

    更新日期:1997-10-01 00:00:00

  • Farnesyltransferase inhibitors.

    abstract::The targeting of molecular abnormalities in neoplasms may provide an opportunity to improve the selectivity of cancer therapy. Ras mutations are a common genetic event in human cancers. Other genetic changes in tumors can signal through ras-dependent pathways as well. The targeting of ras through the inhibition of Ras...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90286-6

    authors: Hahn SM,Bernhard E,McKenna WG

    更新日期:2001-10-01 00:00:00

  • Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.

    abstract::Cyclin dependent kinase (CDK) 4/6 inhibitors have advanced the treatment of metastatic breast cancer by targeting the cell cycle machinery, interrupting intracellular and mitogenic hormone signals that stimulate proliferation of malignant cells. Preclinical evidence demonstrated that derangements of cyclin D1, CDK4/6,...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2018.01.006

    authors: Scott SC,Lee SS,Abraham J

    更新日期:2017-12-01 00:00:00

  • Surgical adjuvant chemotherapy in non-small cell lung cancer.

    abstract::In two different controlled prospective randomized trials the Lung Cancer Study Group has shown that adjuvant CAP chemotherapy is effective in prolonging the disease-free survival. These studies indicate that the adjuvant chemotherapy has its effect by way of diminishing systemic recurrences and that the adjuvant ther...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Holmes EC

    更新日期:1988-06-01 00:00:00

  • Taxoids: effective agents in anthracycline-resistant breast cancer.

    abstract::The results of recent clinical trials have shown that docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France), like paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), has high levels of activity in patients with anthracycline-resistant breast cancer. Agents that are at least partially non-cross-resist...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ravdin PM

    更新日期:1995-12-01 00:00:00

  • Metabolism and action of fludarabine phosphate.

    abstract::Fludara I.V. (fludarabine phosphate) (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A) is an adenine nucleoside analogue resistant to adenosine deaminase that shows promising therapeutic activity in the clinical treatment of lymphocytic hematologic malignancies. F-ara-A is transported into cells, where it is converted to...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Plunkett W,Huang P,Gandhi V

    更新日期:1990-10-01 00:00:00

  • Vascular toxicity of antineoplastic agents.

    abstract::Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.11.006

    authors: Shahab N,Haider S,Doll DC

    更新日期:2006-02-01 00:00:00

  • Recent advances in pathologic evaluation and reporting of melanoma.

    abstract::Recent changes to the staging of melanoma, coupled with advances in surgical and medical treatment, have resulted in new methods for diagnostic evaluation and reporting of melanocytic lesions by pathologists. This review provides an update on recent changes in evaluation and reporting of primary melanoma, evaluation o...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2012.01.005

    authors: Mathew R,Messina JL

    更新日期:2012-04-01 00:00:00

  • Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.

    abstract::The activity of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has been documented in untreated and previously treated metastatic breast cancer, including both patients with anthracycline-resistant disease and those with extensive pretreatment. Such activity has prompted investigations of...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dombernowsky P,Gehl J,Boesgaard M,Jensen TP,Jensen BV

    更新日期:1996-02-01 00:00:00

  • Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

    abstract::Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Manegold C

    更新日期:1998-08-01 00:00:00

  • Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer.

    abstract::The purpose of this pilot study was to determine the safety and feasibility of accelerated fractionation (via concomitant boost) radiotherapy (XRT) with concurrent carboplatin/paclitaxel chemotherapy for locally advanced stage III non-small cell lung carcinoma. Radiotherapy consisted of 3-dimensional conformal techniq...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2005.03.004

    authors: Machtay M,Washam C,Devine P

    更新日期:2005-04-01 00:00:00

  • The role of music therapy in palliative medicine and supportive care.

    abstract::This paper is designed to provide an introduction to music therapy in the continuum of cancer care. The value and use of music therapy during diagnosis and treatment, palliation, hospice, actively dying, and bereavement have been well documented. The music therapy process will be identified, research will be shared, a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2011.03.010

    authors: Gallagher LM

    更新日期:2011-06-01 00:00:00

  • The use of ondansetron in patients receiving multiple-day cisplatin regimens.

    abstract::The control of nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy has remained difficult, even with the use of combination antiemetic regimens containing metoclopramide. Although these patients receive a lower daily dose of cisplatin, the emetogenic potential remains high. In addition, many ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:1992-08-01 00:00:00

  • A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome.

    abstract::From February 1985 to June 1993, 173 consecutive, previously untreated patients with small cell lung cancer received individualized treatment tailored to disease extent. Almost all patients (14 of 16) with stage I and II disease and 30 patients with operable stage III disease were submitted to surgery preceded or foll...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Santoro A,Parra HS,Bidoli P,Angelidou M,Cataldo I,Salvini P,Valagussa P,Milani F,Ravasi G,Bonadonna G

    更新日期:1995-02-01 00:00:00

  • Surgery for support and palliation in patients with malignant disease.

    abstract::Surgery is the major curative treatment modality for patients with malignant disease. However, surgery also plays an important role in supportive and palliative care of cancer patients. In settings in which maintaining quality of life rather than prolongation of survival is the major goal of treatment, the potential m...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Markman M

    更新日期:1995-04-01 00:00:00

  • Metastatic and histologic presentations in unknown primary cancer.

    abstract::The patient with metastatic adeno- or undifferentiated carcinoma who presents with a cryptic primary is subjected to an extensive diagnostic search. These efforts apparently stem from the following assumptions: 1). The ultimately proven primary sites in such patients will occur with the same frequency as the most comm...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Nystrom JS,Weiner JM,Heffelfinger-Juttner J,Irwin LE,Bateman JR,Wolf RM

    更新日期:1977-03-01 00:00:00

  • Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.

    abstract::Combinations of active antineoplastic agents have been the most effective treatment for metastatic breast cancer. Criteria for an effective combination include use of drugs with different mechanisms of action, nonoverlapping toxic effects, and synergistic, or at least additive, antitumor activity. Paclitaxel (Taxol; B...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Holmes FA

    更新日期:1996-10-01 00:00:00

  • Total necrosis of hepatocellular carcinoma with a combination therapy of arterial infusion of chemotherapeutic lipiodol and transcatheter arterial embolization: report of 14 cases.

    abstract::Combination therapy consisting of Lipiodol (Laboratoire Guerbet, Villepinte, France) containing styrene maleic acid neocarzinostatin and transcatheter arterial embolization (L-TAE) has been an important conservative therapy for hepatocellular carcinoma (HCC). We examined the clinical and pathologic characteristics of ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Kenji J,Hyodo I,Tanimizu M,Tanada M,Nishikawa Y,Hosokawa Y,Mandai K,Moriwaki S

    更新日期:1997-04-01 00:00:00

  • Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.

    abstract::Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and in...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.06.002

    authors: Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA

    更新日期:2006-10-01 00:00:00

  • Palliative radiation therapy.

    abstract::Radiation is an effective modality to aid in symptom management of patients with metastatic disease. The type and duration of treatment depends on the Karnofsky performance status (KPS) of the patient and type and status of the cancer. Abbreviated treatment regimens may be favored in this patient population. They prov...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.11.013

    authors: Konski A,Feigenberg S,Chow E

    更新日期:2005-04-01 00:00:00

  • Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.

    abstract::The purpose of this study is to evaluate the efficacy and safety of a biweekly neoadjuvant docetaxel/gemcitabine regimen in patients with histologically confirmed stage II and III breast cancer. In addition, a cDNA microarray study attempted to correlate pretreatment gene-expression profile with clinical and pathologi...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:10.1053/j.seminoncol.2004.03.025

    authors: Estévez LG,Sánchez-Rovira P,Dómine M,León A,Calvo I,Jaén A,Casado V,Rubio G,Daz M,Miró C,Lobo F

    更新日期:2004-04-01 00:00:00

  • Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis.

    abstract::Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1016/s0093-7754(01)90025-9

    authors: Munshi NC,Wilson C

    更新日期:2001-12-01 00:00:00

  • Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

    abstract::In the last decade our understanding of chronic lymphocytic leukemia (CLL) biology and pathogenesis has increased substantially. These insights have led to the development of several new agents with novel mechanisms of action prompting a change in therapeutic approaches from chemotherapy-based treatments to targeted t...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.02.007

    authors: Herman SE,Wiestner A

    更新日期:2016-04-01 00:00:00

  • Modeling toxicity and response in carboplatin-based combination chemotherapy.

    abstract::Data from women with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III or IV) were analyzed to evaluate the pharmacokinetic/pharmacodynamic relationships of carboplatin-based combination chemotherapy. With the equation area under the plasma concentration versus time curve (AUC) =...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Egorin MJ,Reyno LM,Canetta RM,Jodrell DI,Swenerton KD,Pater JL,Burroughs JN,Novak MJ,Sridhara R

    更新日期:1994-10-01 00:00:00

  • Liver transplantation in Langerhans' cell histiocytosis (histiocytosis X).

    abstract::Two children with biopsy-proven LCH underwent successful hepatic transplantation for end-stage liver disease. These patients were thought not to have active LCH disease at the time of transplantation, although one had developed a new osteolytic lesion a few months before the operation and the other had suspicious oste...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Concepcion W,Esquivel CO,Terry A,Nakazato P,Garcia-Kennedy R,Houssin D,Cox KL

    更新日期:1991-02-01 00:00:00

  • Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: A systemic review.

    abstract:BACKGROUND:Patients with severe renal impairment or undergoing hemodialysis are usually excluded from clinical trials. Available data regarding safety and activity of systemic therapies (ST) in hemodialyzed patients are scarce. METHODS:Clinical data were searched through PubMed database until April 2020 according to P...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2020.05.001

    authors: Klajer E,Garnier L,Goujon M,Schlurmann-Constans F,Mery B,Nguyen Tan Hon T,Mouillet G,Calcagno F,Thiery-Vuillemin A

    更新日期:2020-01-01 00:00:00

  • 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate that is preferentially converted to 5-fluorouracil in tumors relative to normal tissue. Three different dosing regimens were investigated in phase I studies: continuous monotherapy, intermittent monotherapy, and intermittent therapy supplemented with le...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1016/s0093-7754(01)90251-9

    authors: Seitz JF

    更新日期:2001-02-01 00:00:00

  • Genetic changes associated with testicular cancer susceptibility.

    abstract::Testicular germ cell tumor (TGCT) is a highly heritable cancer primarily affecting young white men. Genome-wide association studies (GWAS) have been particularly effective in identifying multiple common variants with strong contribution to TGCT risk. These loci identified through association studies have implicated mu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2016.08.004

    authors: Pyle LC,Nathanson KL

    更新日期:2016-10-01 00:00:00